Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.

HIV clinical trials - 1 Jan 2000

Gutiérrez Carolina, Hernández-Novoa Beatriz, Pérez-Elías María Jesús, Moreno Ana María, Holguín Africa, Dronda Fernando, Casado José Luis, Moreno Santiago

Abstract excerpt

BACKGROUND: Raltegravir (RAL) constitutes the first available integrase strand transfer inhibitor (INSTI) available in clinical practice. Three independent pathways have been described to confer resistance to RAL. Secondary mutations with little effect on INSTI susceptibility and additional substitutions with an uncertain role have also been described especially in HIV-1 non-B variants. METHODS: We evaluated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Pyrrolidinones

Share to Quinolones

Share to Raltegravir Potassium

Share to Viral Load

Source

Identifiers

PMID: 23372110
DOI: 10.1310/hct1401-10

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.PMID 23372110Read ↗

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors.Semantic proximity Read ↗

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.Semantic proximity Read ↗

Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study.Semantic proximity Read ↗

Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experienceSemantic proximity Read ↗

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.Semantic proximity Read ↗

Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.Semantic proximity Read ↗

Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infectionSemantic proximity Read ↗

Transmitted Drug Resistance in Nonsubtype B HIV-1 InfectionSemantic proximity Read ↗

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Semantic proximity Read ↗

Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.Semantic proximity Read ↗

In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.Semantic proximity Read ↗

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.